Enveric Biosciences Inc (ENVB)

$0.69 -0.08 (-10.88%)
Market Cap 4.31M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 904,200
Avg Vol 436,550
Day's Range N/A - N/A
Shares Out 6.22M
Stochastic %K 58%
Beta 0.60
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
ChartChartist
ChartChartist Oct. 5 at 1:28 AM
$PAVS $3 - $5 when compliance then news release. Its locked. The rest is shorts playing small. $APVO 1.4 nice $ENVB accumulation $ISPC $1 alert set
0 · Reply
MrTicker
MrTicker Oct. 3 at 9:53 PM
$ENVB new 13G filed
0 · Reply
MrTicker
MrTicker Oct. 3 at 9:52 PM
$ENVB Form SCHEDULE 13G Enveric Biosciences, Filed by: AdvisorShares Trust 10K WIZARD 4:51 PM ET 10/3/2025 http://archive.fast-edgar.com/20251003/AUZZ6G22S222UZZ822242ZZZ5T3EZ2GSZ972 Filed on: October 3, 2025
0 · Reply
FloFloFloFlo
FloFloFloFlo Oct. 3 at 4:53 PM
$ENVB is this at risk of being delisted?
1 · Reply
Johnny_Tubesteak
Johnny_Tubesteak Oct. 3 at 3:25 PM
$ENVB Pullback. Not even a crazy amount of volume. Holds .70-.72 it can climb to .80 next week. Breaks .81ish, rip right up to .90ish. Positive sentiment in my opinion. Momentum is in the upward direction.
0 · Reply
Remolabarca22
Remolabarca22 Oct. 3 at 2:48 PM
$ENVB why you sell? Buy the deep and hold
0 · Reply
Shine1313
Shine1313 Oct. 3 at 2:30 PM
$ENVB what the hell man, why this effing dip
0 · Reply
Gian22
Gian22 Oct. 3 at 1:30 PM
$ENVB all you really idiot selling
0 · Reply
bigterabytes
bigterabytes Oct. 3 at 1:19 PM
$ENVB $NEGG $VWAV $ZM don't miss $QCLS 🚀🚀🚀
0 · Reply
Remolabarca22
Remolabarca22 Oct. 3 at 12:56 PM
$ENVB ?????? Premarket
1 · Reply
Latest News on ENVB
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 2 days ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 16 days ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 17 days ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 17 days ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 18 days ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 4 weeks ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 4 weeks ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 5 weeks ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 7 weeks ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 2 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 2 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 3 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 3 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 4 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 4 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 4 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 5 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 7 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 7 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 7 months ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 7 months ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 8 months ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 8 months ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 8 months ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 30, 2025, 4:01 PM EST - 8 months ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Jan 6, 2025, 8:30 AM EST - 9 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Dec 2, 2024, 8:00 AM EST - 10 months ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 25, 2024, 9:00 AM EST - 11 months ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 14, 2024, 4:05 PM EST - 11 months ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 12, 2024, 9:00 AM EST - 11 months ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Nov 4, 2024, 10:36 AM EST - 11 months ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Aug 12, 2024, 5:30 PM EDT - 1 year ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Jul 15, 2024, 9:02 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences Announces Patent Granted for Drug Candidate

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Patent Granted for Drug Candidate

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

MBIO

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Enveric Biosciences to Participate in BIO International Convention 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Participate in BIO International Convention 2024

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15, 2024, 6:00 AM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 14, 2024, 10:35 AM EDT - 1 year ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

May 8, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

ChartChartist
ChartChartist Oct. 5 at 1:28 AM
$PAVS $3 - $5 when compliance then news release. Its locked. The rest is shorts playing small. $APVO 1.4 nice $ENVB accumulation $ISPC $1 alert set
0 · Reply
MrTicker
MrTicker Oct. 3 at 9:53 PM
$ENVB new 13G filed
0 · Reply
MrTicker
MrTicker Oct. 3 at 9:52 PM
$ENVB Form SCHEDULE 13G Enveric Biosciences, Filed by: AdvisorShares Trust 10K WIZARD 4:51 PM ET 10/3/2025 http://archive.fast-edgar.com/20251003/AUZZ6G22S222UZZ822242ZZZ5T3EZ2GSZ972 Filed on: October 3, 2025
0 · Reply
FloFloFloFlo
FloFloFloFlo Oct. 3 at 4:53 PM
$ENVB is this at risk of being delisted?
1 · Reply
Johnny_Tubesteak
Johnny_Tubesteak Oct. 3 at 3:25 PM
$ENVB Pullback. Not even a crazy amount of volume. Holds .70-.72 it can climb to .80 next week. Breaks .81ish, rip right up to .90ish. Positive sentiment in my opinion. Momentum is in the upward direction.
0 · Reply
Remolabarca22
Remolabarca22 Oct. 3 at 2:48 PM
$ENVB why you sell? Buy the deep and hold
0 · Reply
Shine1313
Shine1313 Oct. 3 at 2:30 PM
$ENVB what the hell man, why this effing dip
0 · Reply
Gian22
Gian22 Oct. 3 at 1:30 PM
$ENVB all you really idiot selling
0 · Reply
bigterabytes
bigterabytes Oct. 3 at 1:19 PM
$ENVB $NEGG $VWAV $ZM don't miss $QCLS 🚀🚀🚀
0 · Reply
Remolabarca22
Remolabarca22 Oct. 3 at 12:56 PM
$ENVB ?????? Premarket
1 · Reply
Remolabarca22
Remolabarca22 Oct. 3 at 9:31 AM
$ENVB
0 · Reply
BullseyeStock
BullseyeStock Oct. 3 at 1:34 AM
GIPR is the type of setup market is loving right now. When more folks finds this, expecting big things! Float is very small on it, so will go up fast! Be early bulls, GIPR has the parabolic look! GIPR ✅Partnerships = increase revenues ✅Go private = They are undervalued currently compared to peers and revenues ✅Joint venture = would increase share price tremendously ✅Sale of the company = they would get probably 4x-5x minimum their yearly revenues. GOOD LIST $AREC $ENVB $BINI $FTEL
0 · Reply
VegasOracle
VegasOracle Oct. 3 at 12:09 AM
$ENVB AUSTRALIA .... Enveric Biosciences advances manufacturing of depression drug candidate By Investing.com https://share.google/e4rumlDWjDrAAGres
0 · Reply
STKH
STKH Oct. 2 at 9:35 PM
$ENVB x done
0 · Reply
VegasOracle
VegasOracle Oct. 2 at 8:07 PM
$ENVB ....a 17.25% move! Buy Buy Buy
0 · Reply
STKH
STKH Oct. 2 at 7:32 PM
$ENVB
0 · Reply
Shine1313
Shine1313 Oct. 2 at 7:20 PM
$ENVB This BEAST is going to touch 5$
1 · Reply
Shine1313
Shine1313 Oct. 2 at 7:19 PM
$ENVB minimum target 5$
0 · Reply
Luckyjs38
Luckyjs38 Oct. 2 at 7:10 PM
$ENVB $CEIN $FAMI 🔮🐦‍🔥
0 · Reply
Shine1313
Shine1313 Oct. 2 at 6:33 PM
$ENVB come on!!
0 · Reply
Remolabarca22
Remolabarca22 Oct. 2 at 4:17 PM
$ENVB hold and buy. Target 5
0 · Reply
ManikMind
ManikMind Oct. 2 at 3:10 PM
$ENVB has cleared the $2.5M Nasdaq listing requirement. Just needs to clear the $1 requirement now. “today announced significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead candidate, EB-003. Important steps for required regulatory activities have been achieved, advancing EB-003 toward human clinical trials.”
0 · Reply